2023-508433-14-00已完成3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
Neurocrine Biosciences Inc.44 个研究点 分布在 6 个国家目标入组 192 人开始时间: 2024年3月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 192
- 试验地点
- 44
- 主要终点
- Change in PANSS total score from baseline to Week 10.
研究概览
简要总结
To evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in subjects who have inadequate response to antipsychotic treatment.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Completed written informed consent in accordance with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) and according to local laws and regulations.
- •The subject's diagnosis, background antipsychotic therapy, and severity of symptoms must be confirmed by the Sponsor or designee prior to the first dose of study treatment on Day
- •The subject must have an adult informant (eg, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse).
- •A body mass index (BMI) of 18.0 to 40.5 kg/m2 (inclusive) at the screening visit.
- •Female subjects of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at Day
- •Female subjects of childbearing potential must agree to use contraception consistently from the screening visit until 30 days after the last dose of study drug or final study visit, whichever is longer.
- •Male subjects must agree to use contraception consistently from screening visit until 30 days after last dose of study treatment.
- •Willing to comply with all study procedures and restrictions; and in the opinion of the investigator, the subject is capable of understanding and complying with all study procedures and restrictions. This criterion must be reconfirmed before the first dose of study treatment on Day
- •At the time of signing the informed consent subject must be ≥18 years of age.
- •Medically confirmed diagnosis of schizophrenia as defined by the DSM-5 and confirmed by the MINI for Psychotic Disorders Version 7.0.
- •The initial diagnosis of schizophrenia must be ≥1 year before the screening visit.
- •The subject is receiving background antipsychotic therapy (other than clozapine) at a total daily dose between 3 mg and 8 mg of risperidone equivalents
- •Plasma levels for at least 1 of the subject's antipsychotic medications must be detectable by an available assay.
- •The subject is treated with a stable regimen antipsychotic medication.
- •Must meet all of the following criteria at screening visit (Visit 1) and Day 1 (Visit 2): • Positive and Negative Syndrome Scale (PANSS) total score ≥70 • PANSS score of ≥4 on at least 1 of the following: - P1 (delusions) - P3 (hallucinations) - P6 (suspiciousness) - G9 (unusual thought content) • Clinical Global Impression of Severity (CGI S) score ≥ 4 • Stable background antipsychotic medication dose between the screening visit and Day 1 • Stable PANSS total score between the screening visit and Day 1
- •The subject is outpatient with stable symptomatology
排除标准
- •Pregnant or breastfeeding or plans to become pregnant during the study. This criterion must be reconfirmed before the first dose of study treatment on Day
- •Subjects with any suicidal behavior or suicidal ideation (Type 4 or 5) within 6 months before the screening visit or on Day
- •Diagnosis of moderate or severe substance use disorder within the 6 months before the screening visit.
- •Positive alcohol test (value ≥0.020%) or urine drug screen for disallowed substances, including amphetamines; barbiturates; cocaine; marijuana; methadone; methamphetamine; 3,4methylenedioxymethamphetamine (MDMA); phencyclidine; or nonprescribed benzodiazepines or opiates.
- •Have a clinically significant unstable medical condition within 60 days before the screening visit in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit.
- •Have any known history of long QT syndrome or cardiac arrhythmia.
- •Have a triplicate average electrocardiogram (ECG) QT interval corrected for heart rate using Fridericia's formula (QTcF) of >450 msec (male subjects) or >470 msec (female subjects) or the presence of any clinically significant cardiac abnormality during the Screening Period.
- •Have a moderate or severe hepatic impairment or chronic elevation of any of the following laboratory tests: Serum creatinine, AST, ALT, GGT, Serum total bilirubin.
- •Laboratory abnormalities of Hemoglobin, White blood cell count, Platelet count or Absolute neutrophil count at the screening visit.
- •Have a hematologic malignancy or solid tumor diagnosed within 3 years before the screening visit or not in remission, with the exception of localized skin cancer or carcinoma in situ of the cervix that has been excised.
- •Have any known history of neuroleptic malignant syndrome.
- •Known hypersensitivity to any component of the formulation of valbenazine.
- •Are currently taking any of the prohibited medications (as described in Section 7.1 of the protocol). Subjects who have received these medications in the past, must have been off them for at least 30 days before the screening visit.
- •Has previously been enrolled and received study treatment in this study (Study NBI-98854-ATS3019) or any other valbenazine clinical trial; has used any active investigational drug in the context of a clinical study within 30 days or 5 half-lives before the screening visit, whichever is longer; has participated in 3 or more clinical studies within 12 months prior before the screening visit; or is currently participating in another clinical study; or has participated in a clinical study for a psychiatric condition that is exclusionary in this protocol.
- •Prior (within 6 months of the screening visit) or concomitant use of any VMAT2 inhibitors.
- •Any reason that makes the subject unsuitable for participation in this study (eg, subject is homeless, known to have difficulty complying with treatment or medical procedures, known to provide inaccurate medical information, or attempt participation in clinical studies inappropriately).
- •Have comorbid Parkinsonism or exhibit more than a minimal level of extrapyramidal sings/symptoms
- •Have a Barnes Akathisia Rating Scale (BARS) global clinical assessment score ≥2 at the screening visit (Visit 1). This criterion must be reconfirmed before the first dose of study treatment on Day
- •Has history of treatment resistant schizophrenia.
- •Diagnosis of schizoaffective disorder; bipolar disorder; or a lifetime diagnosis of obsessive-compulsive disorder.
- •Recent (within the last 6 months before the screening visit) occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions currently requiring clinical attention.
- •Evidence of depression as measured by a Calgary Depression Scale for Schizophrenia (CDSS) score ≥11 at the screening visit or Day
- •Initiation or changes in nonpharmacological psychosocial therapeutic treatment (eg, day hospital treatment, cognitive-behavioral therapy) within 3 weeks before the screening visit or expected to change throughout the length of the study.
结局指标
主要结局
Change in PANSS total score from baseline to Week 10.
Change in PANSS total score from baseline to Week 10.
次要结局
- Change in CGI-S score from baseline to Week 10
- Change in Personal and Social Performance Scale (PSP) score from baseline to Week 10
研究者
Neurocrine Medical Information Call Center
Scientific
Neurocrine Biosciences Inc.
研究点 (44)
Loading locations...
相似试验
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold UrticariaNCT07266402Celldex Therapeutics240
招募中
2 期
Topical Ketotifen 0.25% for Secondary VestibulodyniaNCT07257029Center for Vulvovaginal Disorders54
招募中
1 期
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.Eosinophilic esophagitis2024-512722-28-00Bioprojet Pharma161
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80